 |
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||
 |
||||||
 |
|
|
||||
|
||||||
 |
|
Management Robert B. Stein, MD, PhD Chief Executive Officer David M. Fineman Marc K. Hellerstein, MD, PhD Brent Vaughan, MBA Alexander Glass, PhD Sam Teichman, MD Scott Turner, PhD Koenraad Wiedhaup, PhD Board of Directors David M. Fineman Marc K. Hellerstein, MD, PhD Robert B. Stein, MD, PhD James S. J. Manuso, PhD Jeffrey F. McKelvy, MD, PhD Edward Neugeboren
Robert B. Stein, MD, PhD David M. Fineman Marc K. Hellerstein, MD, PhD Co-Founder, Chairman of the Scientific Advisory Board Dr. Hellerstein joined the faculty of the UC Berkeley, in 1987 after completing medical training at Yale Medical School with a fellowship in endocrinology at New England Medical Center and a PhD in Nutritional Biochemistry from Massachusetts Institute of Technology. He maintains a joint appointments at the University of California, San Francisco, San Francisco General Hospital, and in nutritional sciences at the University of California, Berkeley, where he occupies an endowed chair. Dr. Hellerstein's major research interest has been the measurement of metabolic flux in vivo. By combining powerful technology with novel mathematical approaches and insights into biological systems, his group has measured quantitatively many metabolic processes that could not previously be studied. The potential for applications to clinical diagnostics and drug development led directly to the founding of KineMed, Inc. Dr. Hellerstein has advised numerous pharmaceutical companies, including Abbott Laboratories, Entelos, Agouron Pharmaceuticals, Bayer, Genetech, Parke Davis, Pfizer, and Warner Lambert. Brent A. Vaughan, MBA Chief Business Officer Mr. Vaughan most recently consulted on business development and strategy for Chiron Corporation. He served as vice president, corporate & business development, at Saegis Pharmaceuticals where he actively participated in the successful venture financing and worked with large pharmaceutical companies to in-license the company's lead development compounds and form development alliances. Before Saegis, as director, marketing & business development at Inhale Therapeutics (now Nektar), he led product marketing and worked in business development and alliance management roles. From 1995 to 1997, he worked in international marketing and new business development for Boehringer-Mannheim Corporation and then assisted in the successful divestiture of a key business unit as part of the acquisition of the company by Roche. Mr. Vaughan received a BS in biochemistry from the University of California, Davis, and an MBA from the Leavey School of Business, Santa Clara University. Alexander Glass, PhD Executive Vice President, Instrumentation Dr. Glass leads the company's instrumentation development effort. He formerly was executive director of the Bay Area Regional Technology Alliance (BARTA), a non-profit business-consulting group located in Silicon Valley that focused on assisting early-stage, technology-based companies. Before launching BARTA, Dr. Glass served in several research management positions at the Lawrence Livermore National Laboratory, including assistant director of the laser program, associate director for magnetic fusion and beam research, and laboratory associate director for programs. He also led the US portion of the International Thermonuclear Experimental Reactor project from 1990 to 1992. Dr. Glass previously served as CEO of Chromex, Inc., a manufacturer of optical instruments, and as president and COO of KMS Fusion, a firm conducting contract research and building custom instrumentation systems. From 2001 to 2003, Dr. Glass managed programs for the US Air Force European Office of Aerospace Research and Development, in London. He is currently serves as an advisor to the Asian office of aerospace research & development in Tokyo and is a member of the technical advisory committee for Technology Ventures Corporation, a government-sponsored technology development consulting group located in Livermore, CA. Dr. Glass is also a fellow of the Optical Society of America and the IEEE, a member of the American Physical Society, and has served on the US Air Force scientific advisory board, and the advisory council for the School of Science at Rensselaer Polytechnic Institute. Dr. Glass received his BS in physics from Rensselaer Polytechnic Institute, and his MS and PhD in physics from Yale University. He was formerly chair of electrical engineering at Wayne State University in Detroit and received an honorary degree of doctor of science from Eastern Michigan University in 1983. Sam Teichman, MD Acting Chief Medical Officer For over 20 years, Sam Teichman, MD, has been designing and leading clinical research and drug development programs at biotechnology companies. He has held senior executive positions at Genentech, Medco Research (now part of King Pharmaceuticals), Glycomed (now part of Ligand Pharmaceuticals) and, most recently, VP and Chief Development Officer at ARYx Therapeutics. At ARYx, he staffed and led core project teams that accelerated 3 products from Research into Development, filing 2 US INDs enabling clinical testing, all within 18 months, leading to a significant follow-on private financing and a licensing deal. He was also a founder of the international drug development strategic consulting firm, WinPharm Associates. Dr. Teichman graduated from Columbia University undergraduate and medical schools. He trained in Cardiology at Albert Einstein College of Medicine in New York City. He is Board Certified in Internal Medicine and Cardiology, has more than 40 medical publications, and is a Fellow of both the American College of Physicians and the American College of Cardiology. He was Associate Clinical Professor of Medicine at USCF from 1990-2001. Scott Turner, PhD Vice-President, Research & Development In 2002, Dr. Turner received his PhD in nutritional sciences and toxicology from the University of California at Berkeley. His graduate research focused on the development and application of stable isotope methodology to the study of adipose tissue dynamics in the ob/ob mouse, a well-known model of obesity. Before entering graduate school, he trained for several years as a research technician in the laboratory of Dr. Marc Hellerstein, where he performed GC/MS analysis and physiology studies of glucose and lipid metabolism. After his graduate studies, he joined KineMed, Inc., where he was instrumental in establishing it as the leader in the field of stable isotope research and applications in drug discovery and development. Dr. Turner has authored or co-authored more than 15 papers and holds several patents in the area of metabolic fluxes and stable isotopes methodology. Dr. Turner has been awarded two NIH grants to fund his research into novel in vivo applications of stable isotopes in disease and serves on the editorial board of Biomarker Insights. Within the scope of his duties as Vice President of Operations at KineMed, he most currently leads the research and development efforts in reverse cholesterol transport. Koenraad Wiedhaup, PhD Former Managing Director and President Global R&D Organon/Akzo-Nobel Pharma As a supervisory board member of governmental foundations (such as the Netherlands Genomics Initiative), of the Dutch BioGeneration Ventures Fund, and by having worked together with UK and USA based venture capital firms, Koen Wiedhaup is actively involved in the creation of new life sciences companies. He serves or served on the supervisory and advisory boards of various biotech companies in the USA and Europe, several of which have meanwhile successfully completed an IPO. Wiedhaup is member of advisory councils of several Dutch universities, member of the supervisory board of the CWZ-hospital in Nijmegen and was vice-chairman of the supervisory board of the Academic Medical Centre Maastricht until 2007. Prior to his current activities Dr. Wiedhaup was Group Director of the Pharma group of Akzo-Nobel from 1994 to early 2000. His responsibilities included R&D, Technology and Strategic Planning. From 1977 till 1994 he was, as a member of the board of management of Organon, responsible for Organon’s Global R&D organization. He joined Organon in 1969 after having obtained his Ph.D. at the University of Amsterdam, and having held positions at the San Francisco Medical Center of the University of California, at Stanford University, California, and with Unilever in Rotterdam and London. James S. J. Manuso, PhD, MBA President & Chief Executive Officer SuperGen, Inc. James S. Manuso is president & chief executive officer of SuperGen, Inc., (NASDAQ: SUPG) and company with hematology-oncology products on the market and in development. Most recently he served as president and CEO of Galenica Pharmaceuticals, Inc., a development stage company focused on cancer and infectious disease vaccines. Previously, he co-founded and was a general partner of PrimeTech Partners, a biotechnology venture management partnership, and managing general partner of the corporate advisory firm, The Channel Group, an international life sciences corporate advisory firm. Before co-founding PrimeTech Partners in 1998, Dr. Manuso was co-founder and president of Manuso, Alexander & Associates, Inc., management consultants and financial advisors to pharmaceutical and biotechnology companies. From 1974 until 1983, Dr. Manuso was an officer of The Equitable Companies, where he served as acting medical director and director of health care planning and development. Dr. Manuso earned a BA with honors in economics and chemistry from New York University, a PhD in experimental psychophysiology from The Graduate Faculty of the New School University, a certificate in healthcare management from Harvard Business School and an executive MBA from Columbia Business School. Dr. Manuso taught and lectured at Columbia, NYU, Georgetown University, Polytechnic University, and Waseda University (Japan). Jeffrey F. McKelvy, MD, PhD President and Chief Technical Officer Dr. McKelvy is president and CEO of ItherX, Inc. He was CTO of Avera Pharmaceuticals, an emerging pharmaceutical company focused on the acquisition, development and commercialization of novel pharmaceutical compounds in the neuroscience therapeutics arena. Before joining the founding team of Avera, Dr. McKelvy was vice president of Merck Research Laboratories and head of their San Diego site in 1999 after Merck's acquisition of SIBIA Neurosciences, Inc. In that capacity, he oversaw the integration of SIBIA into Merck Research Laboratories. Dr. McKelvy joined SIBIA Neurosciences, Inc., a publicly traded biotechnology company as executive vice president, chief scientific officer and director in 1998. Before SIBIA, Dr. McKelvy was founding CEO of Trophix Pharmaceuticals, Inc., a private biotechnology company in 1997. He then led the acquisition of Trophix by Allelix Biopharmaceuticals, Inc., of Ontario, Canada, and played a transitional role for the integration of the new company as senior vice president for neuroscience. Before Trophix, Dr. McKelvy served as vice president of the central nervous system strategic business unit for CIBA, where he managed a large portfolio of clinical development candidates for depression and anxiety. In 1987, he left his position as professor of neurobiology, molecular biology and psychiatry at SUNY Stony Brook and chairman of the neuroscience research review committee of the National Institutes of Mental Health, to join Abbott Laboratories, first as area head for neuroscience drug discovery and then as founding venture head for the neuroscience venture. While at Abbott, Dr. McKelvy established joint ventures with NOVO/NORDISK, resulting in the registration and marketing of the novel antiepileptic drug GABITRIL®, and with H. Lundbeck A.S., which resulted in the registration and marketing of SERLECT®, a novel antipsychotic drug. Dr. McKelvy received his medical and scientific training at Case Western Reserve School of Medicine and Johns Hopkins University. He is currently adjunct professor of psychiatry at University of California, San Diego, School of Medicine. Edward Neugeboren Managing Partner Ledgemont Capital Group, LLC Mr. Neugeboren is a managing partner of Ledgemont Capital Group, LLC (formerly IndiGo Ventures LLC), a boutique investment banking firm based in New York. Mr. Neugeboren has experience in portfolio management, corporate management and equity research. Previously, Mr. Neugeboren was a managing partner of Third Ridge Capital Management, LLC, a U.S. equity hedge fund. He has also served as Chief Administrative Officer of Sorceron, an emerging Silicon Alley-based media software company, from October 2000 to April 2001. Mr. Neugeboren was chief administrative officer and director of equity research operations at Lehman Brothers from 1998 to 2000. He was deputy director of equity research at UBS Warburg, formerly Warburg Dillon Read from 1996 to 1998 and director of equity research operations from 1995 to 1996. Mr. Neugeboren was a senior member of the management team as well the investment policy and equity commitment committees. He graduated with a BS in economics from Union College in 1992. |
|
|